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ABSTRACT
Background:
Several meta-analyses have tried to deﬁ ne the role of minimally invasive approaches. 
However, further evidence to get a wider spread of these methods is necessary. Current 
studies describe minimally invasive surgery as a possible alternative to open surgery 
but deserving further clariﬁ cation. However, despite the increasing interest, the 
diﬃ  culty of planning prospective studies of adequate size accounts for the low level of 
evidence, which is mostly based on retrospective experiences.
A multi-institutional prospective study allows the collection of an impressive amount 
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of data to investigate various aspects of minimally invasive procedures with the 
opportunity of developing several subgroup analyses. 
A prospective data collection with high methodological quality on minimally invasive 
and open gastrectomies can clarify the role of diﬀ erent procedures with the aim to 
develop speciﬁ c guidelines.
Methods and analysis:
a multi-institutional prospective database will be established including information on 
surgical, clinical and oncological features of patients treated for gastric cancer with 
robotic, laparoscopic or open approaches and subsequent follow-up.
The study has been shared by the members of the International study group on 
Minimally Invasive surgery for GASTRIc Cancer (IMIGASTRIC)
The database is designed to be an international electronic submission system and a 
HIPPA protected real time data repository from high volume gastric cancer centers.
Ethics:
This study is conducted in compliance with ethical principles originating from the 
Helsinki Declaration, within the guidelines of Good Clinical Practice and relevant 
laws/regulations.
Trial registration number:
NCT02751086
© The Author(s) 2019. Published by ED Marketing & Communication. All rights reserved.
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Background
Oncologic gastric surgery represents a major À eld of 
interest and development for minimally invasive surgery. 
Several institutions have continuously published 
reports regarding their experiences and progress, which 
has allowed authors of systematic reviews and meta-
analysis to try to deÀ ne the role of minimally invasive 
surgery (laparoscopy, robotic) by comparing it with the 
open approach[1-3]. 
However, the current level of evidence has not yet 
allowed for deÀ ning and sharing rules for the application 
of minimally invasive approaches in common surgical 
practice.
Guidelines describe laparoscopy as a possible alternative 
to open surgery for early gastric cancer[4]; meanwhile, 
robotic surgery possesses intrinsic technological 
advantages. However, researchers have not yet veriÀ ed 
these advantages through studies with an appropriate 
level of evidence[5]. Research in this À eld aims to 
assess the effects on perioperative outcomes and the 
patient’s quality of life while still respecting oncological 
principles. The increasing attention that researchers 
have paid to these approaches are unfortunately limited 
by the incomplete data currently available[5].
Robotic systems have revolutionized the way we 
perform minimally invasive surgery and have facilitated 
the evolution of traditional laparoscopy. Surgeons can 
overcome the limits of traditional laparoscopy through 
three-dimensional vision, articulated instruments, and 
the absence of tremors, thus creating greater dexterity 
and precision in dissection and suturing movements. 
These are key elements when performing an extended 
lymphadenectomy for gastric cancer, and complex and 
gentle reconstruction to restore digestive continuity.
Despite the technological advances, several issues are 
currently subject to debate. The most important issue is 
ensuring proper oncological surgery by performing an 
adequate lymphadenectomy with minimally invasive 
approaches. Researchers still regard nodal clearance as 
an important factor inÁ uencing long-term survival[6-13]. 
In randomized trials[3], laparoscopy demonstrated 
the removal of at least 15 lymph nodes, as required 
by international guidelines[14]; however, a signiÀ cant 
difference in favor of open surgery resulted in the total 
number of lymph nodes harvested.
Robotic surgery can facilitate better D2 dissection. 
This advanced technology clearly possesses intrinsic 
advantages for this surgical step, but researchers have 
not yet proven and veriÀ ed them through appropriate 
trials: only four studies[15-18] have compared robotic 
surgery with the open approach, and only one study 
shows a statistically signiÀ cant difference versus 
laparoscopy[19].
Among the intraoperative outcomes, most of the 
available studies found that blood loss was in favor of 
minimally invasive surgery. This À nding has achieved 
high statistical signiÀ cance for laparoscopy in Vinuela’s 
meta-analysis of RCTs[3]. Meanwhile, with regard to 
robotic surgery, a general consensus among different 
studies seems to have detected some advantages over 
laparoscopy and open surgery in reducing operative 
bleeding[19, 20]. However, several studies have also 
reported conÁ icting results[21, 22].
Regarding the post-operative period, the largest 
RCT[23], which was performed by the Korean 
Laparoscopic Gastrointestinal Surgery Study Group, 
found no signiÀ cant difference between laparoscopy and 
open surgery in overall complications. Other studies[3] 
have shown a signiÀ cant reduction in medical and 
minor surgical complications when using laparoscopy. 
Researchers have obtained inconsistent À ndings in 
studies on robotic surgery in terms of demonstrating 
differences compared to laparoscopy in the analysis of 
complications[22, 24, 25].
Overall, minimally invasive surgery has demonstrated 
relevant advantages over open surgery with regard 
to postoperative hospital stays[1, 26-28], despite the 
extreme heterogeneity among studies. Some evidence[18, 
29] has indicated that patients who underwent robotic 
gastrectomy could be discharged at an earlier date 
than patients who underwent open or laparoscopic 
gastrectomy. However, the low number of studies in this 
À eld and the high heterogeneity weaken this conclusion.
Manually handling organs during surgery is an 
important contributor to the inÁ ammatory response 
after surgery[27, 28, 30]. Theoretically, smaller robotic 
instruments may cause less inÁ ammation than the 
instruments used in other approaches. Therefore, 
postoperative bowel recovery in the robotic group may 
occur sooner, but this hypothesis still must be proven.
New research must contribute to the current literature in 
order to deÀ ne the role of different surgical approaches, 
and researchers still have to explore many aspects of 
minimally invasive surgery for gastric cancer[5, 31, 
32]. We have a long way to go. Currently, the scientiÀ c 
community is wondering what strategies should be 
adopted in future studies.
Rationale
A review of the scientiÀ c literature[5], which was 
recently published by the IMIGASTRIC study group, 
aimed to perform a more complete analysis of the current 
situation regarding performing minimally invasive 
surgery for gastric cancer. SigniÀ cant limitations were 
found in the analyzed studies, including:
- Small samples of patients, mostly low-quality 
comparative studies
- Selection bias in the comparison groups (e.g. stage, 
extent of lymphadenectomy)
- Absence of subgroup analysis in signiÀ cant research 
À elds
- Lack of information on the surgical techniques adopted
A large prospective multicenter registry could thus be 
the optimal way to clarify the role of minimally invasive 
surgery for gastric cancer and permit the evaluation 
of its short and long-term effects. A working basis for 
analyzing outcomes of interest and obtaining directions 
for guidelines and future study developments can also 
be created. The following would be the main advantages 
of a large prospective multicenter registry:
-Achieving a large sample of patients
-Collecting multiple variables, allowing for the making 
of a comprehensive statistical report
-Standardizing the methodology to be adopted, thus 
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increasing accuracy
-Bringing together the experiences of both East and West 
to discover shared points
A prospective registry can become a powerful tool that 
can guide research in this À eld to new developments and 
pave the way for other investigational opportunities.
Preliminary data
A research group was À rst established in 2014 and after 
sharing a speciÀ c study protocol, data collection ofÀ cially 
started at the end of 2015 through a retrospective chart 
review (IMIGASTRIC)[5, 32, 33].
More than 4200 cases have been entered in the registry 
to date.
60% of entered cases are from Asia, but over 1600 cases 
were collected by western institutions. About 2600 
patients underwent a MIS approach.
A À rst comparison including a matching analysis 
regarding operative results, postoperative recovery, and 
complications was published[34].
The operative time was signiÀ cantly longer in the Robotic 
group than the other two groups. A statistical difference 
in favor of the open group was also observed when 
compared with the laparoscopic group. A reduction in 
blood loss resulted in favor of both minimally invasive 
approaches vs the open group and particularly slightly in 
favor of the laparoscopic group when compared with the 
robotic group. Regarding the number of retrieved lymph 
nodes, MIS conÀ rmed to guarantee an adequate number 
of nodes for pathological assessment with no signiÀ cant 
difference with the open approach. No differences were 
found regarding intraoperative complications or the 
residual tumor status. The conversion rate was 5.3% in 
the LG and 4.6% in the RG with no signiÀ cant difference.
A signiÀ cantly shorter hospital stay was found in both 
MIS group vs the OG, without differences between the 
LG and RG.
All steps in the patients’ recovery status happened faster 
in both minimally invasive approaches than the open 
surgery. A small beneÀ t was found to be signiÀ cant in 
the minimally invasive groups vs the OG in intravenous 
analgesic discontinuation. The other outcomes showed a 
slight advantage in favor of minimally invasive surgery.
A decrease in the number of patients experiencing 
postoperative complications was shown in both the 
robotic and laparoscopic group versus the open group, 
however this difference was not statistically signiÀ cant. 
No differences were shown in surgical and non-
surgical complications, as well as regarding the type 
of complication. Leakage, bleeding, and pancreatic 
À stula were the most observed surgical complications. 
Pneumonia and urinary were the most common medical 
complications. Majority of cases were low grade 
complications based on the Clavien Dindo classiÀ cation 
(76.9%, overall). The number of patients requiring 
reoperation did not differ among the three groups.
Anastomotic leakage was the most relevant surgical 
complication. Therefore, further analysis is reported. 
No differences in the overall leakage rate was shown 
between groups, as well as the distribution by different 
sites. The leak-related reoperation rate did not differ 
among the three groups.
Laparoscopic and robotic surgery, in this report, 
showed safety in ensuring oncological radicality with 
short hospitalization, beneÀ ts in all patients’ functional 
recovery steps and a lower trend in complications rates.
Methods and analysis
General study design:
The overall purpose is to develop and maintain a 
multi-institutional database comprising of information 
regarding surgical, clinical and oncological features 
of patients that will be treated for gastric cancer with 
robotic, laparoscopic or open approaches and subsequent 
follow-up.
The main objective is to compare the three surgical arms 
on surgical and clinical outcomes, as well as on the 
oncological follow-up.
SpeciÀ c aims:
AIM 1: To compare robotic and laparoscopic surgery 
to the open approach in terms of safety and feasibility 
based on the intraoperative outcomes.
AIM 2: To verify the respect of oncological principles 
through minimally invasive approaches by comparing 
histopathological À ndings to open surgery.
AIM 3: To compare the three treatment arms regarding 
the postoperative course.
AIM 4: To compare the incidence, types and severity of in-
hospital and long-term complications after gastrectomy 
by the three approaches according to the Clavien-Dindo 
classiÀ cation system[35]
AIM 5: To verify whether minimally invasive approaches 
ensure the same effectiveness as open surgery in terms 
of overall survival and disease-free survival at the 
scheduled endpoints.
Eligibility
Every patient is required to meet all the inclusion criteria 
and none of the exclusion criteria.
Inclusion criteria
• Histologically proven gastric cancer
• Preoperative staging work-up performed by 
upper endoscopy and/or endoscopic ultrasound, 
and CT scan and in accordance to international 
guidelines[14]
• Early Gastric Cancer
• Advanced Gastric Cancer
• Patients treated with curative intent in accordance 
to international guidelines[14]
Exclusion criteria
• Distant metastases: peritoneal carcinomatosis, 
liver metastases, distant lymph node metastases, 
Krukenberg tumors, involvement of other organs
• Patients with high operative risk as deÀ ned by the 
American Society of Anesthesiologists (ASA) score 
> 4
• History of previous abdominal surgery for gastric 
cancer
• Synchronous malignancy in other organs
• Palliative surgery
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Data collection (main variables)
Patient Demographics
• Year of birth
• Sex
• BMI
• Surgical risk (ASA score)
• Concomitant illness
• Previous surgery
• Staging laparoscopy
• Neoadjuvant chemo/radio-therapy
• Pre-operative blood samples
Surgery
• Operation date
• Type of surgical approach (Open, Laparoscopy, 
Robotic)
• Type of gastric resection (Total gastrectomy, Distal 
gastrectomy, Pylorus-preserving gastrectomy, 
Proximal gastrectomy)
• Type of recostruction
• Anastomosis approach (intracorporeal, 
extracorporeal)
• Anastomosis performance (linear stapler, circular 
stapler, hand-sewn)
• Site and lenght of mini-laparotomy
• Placement of intra abdominal drain
• Placement of nasogastric tube
• Total operative time
• Estimated blood loss
• Conversion to open surgery
• Intraoperative complications
• Extent of lymphadenectomy
• Resection margins
• Surgical radicality (R)
• Number of retrieved lymph nodes
 Tumor
• Location and diameter
• Depth of invasion (T classiÀ cation)
• Number of metastatic lymph nodes
• Lymph node status (N classiÀ cation) 
• AJCC pathological stage
• Histological type
Post-operative clinical À ndings
• ERAS protocols adopted
• Length of postoperative hospital stays
• Patient mobilization (POD no.)
• Liquid diet (POD no.)
• Soft solid diet (POD no.)
• First Á atus (POD no.)
In-hospital post-operative complications
• Type of complication
• Reoperation for complication
• Clavien - Dindo grade[35]
Early and late complications after discharge
• Date of occurrence
• Type of complication
• Death related to the complication
• Need of surgery
Follow-up
• Adjuvant chemo/radio-therapy
• Date of follow up visits
• Patient status at follow-up visits (alive, dead, lost to 
follow-up assessment)
• Disease-free or not during follow-up
Primary outcome measures
• Safety and feasibility of procedures: rate of 
intraoperative complications, rate of intraoperative 
death, rate of conversion to open surgery, average 
of estimated blood loss during surgery.
• Respect of oncological principles: average of 
retrieved lymph nodes, rate of patients achieving 
R0 resection, rate of patients achieving specimen 
margins free of disease, at the histopathological 
analysis.
• Effectiveness of surgery: overall survival and 
disease–free survival achieved at 1, 2, 3, 4, 5 years 
from surgery.
Secondary outcome measures 
• Recovery after surgery: rate of post-operative blood 
transfusion, average of time to patient mobilization, 
average of time to resumption of peristalsis, 
average of time to starting oral intake, average of 
time to À rst Á atus, average of length of intravenous 
antibiotic use, average of length of intravenous 
analgesic use, average of hospitalization after 
surgery until discharge.
• Early and long-term complications after surgery: 
rate of total complications, rate of speciÀ c surgical 
complications, severity of complications scored on 
the Clavien-Dindo classiÀ cation system[35].
Statistical analysis
Based on the data of the registry every investigator 
can perform all the statistical analysis he needs for 
his researchers’ purposes, while a basic analysis for 
monitoring the study will be performed as follows. SPSS 
version 23 will be used to carry out the interim data 
analyses.
The dichotomous variables will be expressed as numbers 
and percentages, while continuous variables as mean 
and SD, or median and IQR (minimum and maximum 
values). Continuous variables will be compared using 
one-way ANOVA analysis of variance with post hoc 
multiple comparison by Tukey’s procedure.
Pearson’s χ2 test or Fisher’s exact test, as appropriate, 
will be used for analysis of categorical data. 
The Z test with the Bonferroni correction will be used 
to evaluate statistical signiÀ cance among the surgical 
approaches: Robotic, Laparoscopy, Open.
For each of these tests a value of α<0.05 will be considered 
statistically signiÀ cant.
Subgroup analysis will be done to evaluate the overall 
survival, by considering patients with follow-up details 
at the data extraction time.
Overall survival will be computed from the day of 
surgery to the day of death or to the last reported follow-
up visit. Overall survival analysis will be performed 
using Kaplan–Meier curves. Comparison between 
different groups will be carried out using the log rank 
test.
Sample size
It is estimated from the IMIGASTRIC I study that 
the rate of procedures performed with minimally 
invasive surgery at referral institutes for gastric cancer, 
considering patients who follow inclusion and exclusion 
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criteria of this protocol, is of 65%.
According to the number and volume of the participating 
centers and to reach a sample of 1000 subjects treated 
with laparoscopic or robotic surgery, is estimated that 
data of at least 1500 patients need to be collected.
Study period and sites
The database will remain open for data collection 
(including the participation of other interested 
Institution) for at least 10 years, considering current 
available funds from the promoting institution (St. 
Mary’s Hospital of Terni). 
It is estimated that the sample size will be reached 
in 5 years. The maximum length of each patient for 
the oncological follow-up is 5 years. Subsequent 
amendments will extend the follow-up period based on 
the progress of the project.
The study has been shared by the members of the 
International study group on Minimally Invasive 
surgery for GASTRIc Cancer (IMIGASTRIC)[32]. The 
group involves some of the most important researchers 
and institutes around the world for the treatment of 
gastric cancer and began working in 2014.
Ethics and dissemination
Ethical aspects
All Investigators agree the study is conducted in 
compliance with ethical principles originating from 
the Helsinki Declaration, with the guidelines of Good 
Clinical Practice (GCP) and with applicable laws.
Investigators shall undertake to act according to the 
rules of the Institutional Review Board (IRB) and Ethics 
Committee (EC) regarding the prospective collection of 
data.
Potential risks and safety management
Participation in the research registry involves the 
potential risks of a breach of 
conÀ dentiality of the medical record information and 
associated privacy of the participants. 
ConÀ dentiality and data security will be ensured by:
1) removing direct participant identiÀ ers; 
2) limiting access to information using the assignment 
of codes; 
3) limiting access to information to center investigators.
Risks are minimized using appropriate tailor-made 
systems.
Data will be collected and recorded by all institutions 
through a speciÀ c online software (https://imigastric.
logix-software.it/).
The system provides the following safeguards:
1. Data entry of patient information complies with the 
most stringent privacy regulations; sensitive data are 
not recorded on a server, but the software generates a 
reference code.
2. For each patient, the system generates an IT folder 
containing six speciÀ c areas to complete.
3. The software is designed to guide the user in data 
entry, thus avoiding the generation of errors.
4. The different À elds are À lled in by selecting the 
various options from drop-down menus available for 
each parameter. All characteristics to be entered have 
been previously standardized, without the need to write 
anything else when À lling in the À elds. Any considered 
variable derives from an analysis of all the data reported 
in previous studies found in the literature and in 
accordance with accepted guidelines[14].
5. The software uses predeÀ ned control instruments.
The data and safety monitoring plan for the research 
registry will involve routine monitoring by the organizing 
committee of any conditions that may negatively impact 
the conÀ dentiality of information contained within the 
research registry. 
In addition, any unauthorized access to medical record 
information contained within the research registry 
or to the database linking the registry information to 
participant direct identiÀ ers will be reported to a data 
and safety monitoring board. 
Study’s website
A Study’s website is available at: www.imigastric.com 
to obtain information and follow the news of the project. 
Contact information for the organizing secretariat and 
the coordinating staff is available there. Interested 
centers can join this prospective registry.
Publications
Each participating center, with equal right, will be able 
to access the data of the registry, perform statistical 
analysis, discuss the results, and freely write scientiÀ c 
manuscripts. However, each study that is generated 
based on the registry must be known by all Centers 
before À nal publication.
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